Who is sponsoring NCT00064194?

NCT00064194 is sponsored by NCIC Clinical Trials Group.

What drugs are being tested in NCT00064194?

Interventions in NCT00064194: selenium, soy protein isolate, vitamin E.

What condition does NCT00064194 study?

NCT00064194 studies Precancerous/Nonmalignant Condition, Prostate Cancer.

Is NCT00064194 still recruiting?

NCT00064194 is currently completed. Last updated 3 April 2020.

Last reviewed 2020-04-03 · How we verify

NCT00064194

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vitamin E, Selenium, and Soy Protein in Preventing Cancer in Patients With High-Grade Prostate Neoplasia

Completed Phase 3 Last updated 3 April 2020

What this trial tests

Phase 3 trial testing selenium in Precancerous/Nonmalignant Condition in 310 participants. Completed in 30 April 2008.

Timeline

28 November 2001

Primary endpoint
30 April 2008

30 April 2008

Quick facts

Lead sponsor	NCIC Clinical Trials Group
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Masking	triple
Primary purpose	prevention
Enrollment	310
Start date	28 November 2001
Primary completion	30 April 2008
Estimated completion	30 April 2008
Sites	3 locations across Canada

Drugs / interventions tested

selenium (SELENIUM) — full drug profile →
soy protein isolate — full drug profile →
vitamin E (VITAMIN E) — full drug profile →

Conditions studied

Precancerous/Nonmalignant Condition — all drugs for Precancerous/Nonmalignant Condition →
Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

NCIC Clinical Trials Group

Who can join

Under 120, male only, with Precancerous/Nonmalignant Condition or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development or recurrence of cancer. Vitamin E, selenium, and soy protein may be effective in preventing the development of prostate cancer. PURPOSE: Randomized phase III trial to study the effectiveness of combining vitamin E, selenium, and soy protein in preventing prostate cancer in patients who have high-grade prostate neoplasia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity.
Radomska D, Czarnomysy R, Radomski D, Bielawska A, et al · · 2021 · cited 63× · PMID 34068374 · DOI 10.3390/nu13051649
Chemoprevention of prostate cancer with nutrients and supplements.
Van Poppel H, Tombal B. · · 2011 · cited 21× · PMID 21629831 · DOI 10.2147/cmr.s18503

Verify or expand the search:

Other recruiting trials for Precancerous/Nonmalignant Condition

Currently open trials in the same condition.

NCT00544115 — Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders · Phase 2 · active not recruiting

Other NCIC Clinical Trials Group trials

Trials by the same sponsor.

NCT01916187 — Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma · Phase 1 · withdrawn
NCT01830621 — BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma · Phase 3 · completed
NCT01652144 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma · Phase 2 · completed
NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed
NCT01486368 — A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00064194 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NCIC Clinical Trials Group
Last refreshed: 3 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00064194.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing